Antibiotic resistance of pathogenic Acinetobacter species and emerging combination therapy

Bora Shin, Woojun Park

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

The increasing antibiotic resistance of Acinetobacter species in both natural and hospital environments has become a serious problem worldwide in recent decades. Because of both intrinsic and acquired antimicrobial resistance (AMR) against last-resort antibiotics such as carbapenems, novel therapeutics are urgently required to treat Acinetobacter-associated infectious diseases. Among the many pathogenic Acinetobacter species, A. baumannii has been reported to be resistant to all classes of antibiotics and contains many AMR genes, such as blaADC (Acinetobacter-derived cephalosporinase). The AMR of pathogenic Acinetobacter species is the result of several different mechanisms, including active efflux pumps, mutations in antibiotic targets, antibiotic modification, and low antibiotic membrane permeability. To overcome the limitations of existing drugs, combination theraphy that can increase the activity of antibiotics should be considered in the treatment of Acinetobacter infections. Understanding the molecular mechanisms behind Acinetobacter AMR resistance will provide vital information for drug development and therapeutic strategies using combination treatment. Here, we summarize the classic mechanisms of Acinetobacter AMR, along with newly-discovered genetic AMR factors and currently available antimicrobial adjuvants that can enhance drug efficacy in the treatment of A. baumannii infections.

Original languageEnglish
Pages (from-to)837-849
Number of pages13
JournalJournal of Microbiology
Volume55
Issue number11
DOIs
Publication statusPublished - 2017 Nov 1

Fingerprint

Acinetobacter
Microbial Drug Resistance
Anti-Bacterial Agents
Therapeutics
Acinetobacter Infections
Cephalosporinase
Carbapenems
R Factors
Drug Combinations
Pharmaceutical Preparations
Communicable Diseases
Permeability
Mutation
Membranes
Infection
Genes

Keywords

  • Acinetobacter
  • adjuvants
  • biofilm
  • membrane permeability
  • multidrug resistance
  • natural compounds

ASJC Scopus subject areas

  • Microbiology
  • Applied Microbiology and Biotechnology

Cite this

Antibiotic resistance of pathogenic Acinetobacter species and emerging combination therapy. / Shin, Bora; Park, Woojun.

In: Journal of Microbiology, Vol. 55, No. 11, 01.11.2017, p. 837-849.

Research output: Contribution to journalReview article

@article{fefb920203334bdbbbe44056cfd8aa45,
title = "Antibiotic resistance of pathogenic Acinetobacter species and emerging combination therapy",
abstract = "The increasing antibiotic resistance of Acinetobacter species in both natural and hospital environments has become a serious problem worldwide in recent decades. Because of both intrinsic and acquired antimicrobial resistance (AMR) against last-resort antibiotics such as carbapenems, novel therapeutics are urgently required to treat Acinetobacter-associated infectious diseases. Among the many pathogenic Acinetobacter species, A. baumannii has been reported to be resistant to all classes of antibiotics and contains many AMR genes, such as blaADC (Acinetobacter-derived cephalosporinase). The AMR of pathogenic Acinetobacter species is the result of several different mechanisms, including active efflux pumps, mutations in antibiotic targets, antibiotic modification, and low antibiotic membrane permeability. To overcome the limitations of existing drugs, combination theraphy that can increase the activity of antibiotics should be considered in the treatment of Acinetobacter infections. Understanding the molecular mechanisms behind Acinetobacter AMR resistance will provide vital information for drug development and therapeutic strategies using combination treatment. Here, we summarize the classic mechanisms of Acinetobacter AMR, along with newly-discovered genetic AMR factors and currently available antimicrobial adjuvants that can enhance drug efficacy in the treatment of A. baumannii infections.",
keywords = "Acinetobacter, adjuvants, biofilm, membrane permeability, multidrug resistance, natural compounds",
author = "Bora Shin and Woojun Park",
year = "2017",
month = "11",
day = "1",
doi = "10.1007/s12275-017-7288-4",
language = "English",
volume = "55",
pages = "837--849",
journal = "Journal of Microbiology",
issn = "1225-8873",
publisher = "Microbiological Society of Korea",
number = "11",

}

TY - JOUR

T1 - Antibiotic resistance of pathogenic Acinetobacter species and emerging combination therapy

AU - Shin, Bora

AU - Park, Woojun

PY - 2017/11/1

Y1 - 2017/11/1

N2 - The increasing antibiotic resistance of Acinetobacter species in both natural and hospital environments has become a serious problem worldwide in recent decades. Because of both intrinsic and acquired antimicrobial resistance (AMR) against last-resort antibiotics such as carbapenems, novel therapeutics are urgently required to treat Acinetobacter-associated infectious diseases. Among the many pathogenic Acinetobacter species, A. baumannii has been reported to be resistant to all classes of antibiotics and contains many AMR genes, such as blaADC (Acinetobacter-derived cephalosporinase). The AMR of pathogenic Acinetobacter species is the result of several different mechanisms, including active efflux pumps, mutations in antibiotic targets, antibiotic modification, and low antibiotic membrane permeability. To overcome the limitations of existing drugs, combination theraphy that can increase the activity of antibiotics should be considered in the treatment of Acinetobacter infections. Understanding the molecular mechanisms behind Acinetobacter AMR resistance will provide vital information for drug development and therapeutic strategies using combination treatment. Here, we summarize the classic mechanisms of Acinetobacter AMR, along with newly-discovered genetic AMR factors and currently available antimicrobial adjuvants that can enhance drug efficacy in the treatment of A. baumannii infections.

AB - The increasing antibiotic resistance of Acinetobacter species in both natural and hospital environments has become a serious problem worldwide in recent decades. Because of both intrinsic and acquired antimicrobial resistance (AMR) against last-resort antibiotics such as carbapenems, novel therapeutics are urgently required to treat Acinetobacter-associated infectious diseases. Among the many pathogenic Acinetobacter species, A. baumannii has been reported to be resistant to all classes of antibiotics and contains many AMR genes, such as blaADC (Acinetobacter-derived cephalosporinase). The AMR of pathogenic Acinetobacter species is the result of several different mechanisms, including active efflux pumps, mutations in antibiotic targets, antibiotic modification, and low antibiotic membrane permeability. To overcome the limitations of existing drugs, combination theraphy that can increase the activity of antibiotics should be considered in the treatment of Acinetobacter infections. Understanding the molecular mechanisms behind Acinetobacter AMR resistance will provide vital information for drug development and therapeutic strategies using combination treatment. Here, we summarize the classic mechanisms of Acinetobacter AMR, along with newly-discovered genetic AMR factors and currently available antimicrobial adjuvants that can enhance drug efficacy in the treatment of A. baumannii infections.

KW - Acinetobacter

KW - adjuvants

KW - biofilm

KW - membrane permeability

KW - multidrug resistance

KW - natural compounds

UR - http://www.scopus.com/inward/record.url?scp=85032390411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032390411&partnerID=8YFLogxK

U2 - 10.1007/s12275-017-7288-4

DO - 10.1007/s12275-017-7288-4

M3 - Review article

C2 - 29076065

AN - SCOPUS:85032390411

VL - 55

SP - 837

EP - 849

JO - Journal of Microbiology

JF - Journal of Microbiology

SN - 1225-8873

IS - 11

ER -